<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110935">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883765</url>
  </required_header>
  <id_info>
    <org_study_id>SCHO 1448/2-1</org_study_id>
    <nct_id>NCT01883765</nct_id>
  </id_info>
  <brief_title>Efficacy of Neurofeedback Training in Adults With ADHD</brief_title>
  <official_title>Efficacy of a Neurofeedback Treatment in Adults With ADHD: a Double-blind Randomized Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurofeedback training (NFT) has been frequently investigated as an alternative treatment
      for ADHD mainly in children and adolescents. However, randomized double-blind trials that
      include a sham-neurofeedback control group are lacking, as well as studies examining the
      efficacy of NFT in adult ADHD populations. The inclusion of a sham-neurofeedback group is
      crucial to monitor and exclude unspecific effects.

      This study aims to investigate the efficacy of NFT as compared to a sham-feedback condition
      and a cognitive behavioral treatment in adults with persistent ADHD.

      Efficacy is assessed on several outcome parameters, such as symptom severity,
      neuropsychological variables (e.g., attention, memory), and event related potentials in the
      EEG.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in ADHD symptomatology</measure>
    <time_frame>baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological variables</measure>
    <time_frame>baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Attention (Continuous Performance Test, N-back) Interference (Stroop) Set-Shifting (Set-Shifting Paradigm) Impulsiveness/Response Control (Go-Nogo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-related potentials</measure>
    <time_frame>baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>emitted P 300 Contingent Negative Variation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Attention Deficit-hyperactivity Disorder in Adults</condition>
  <arm_group>
    <arm_group_label>Neurofeedback active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active neurofeedback training, theta/beta-protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurofeedback sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Neurofeedback training is simulated to subjects in this condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metacognitive Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metacognitive training, cognitive behavioral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurofeedback active</intervention_name>
    <arm_group_label>Neurofeedback active</arm_group_label>
    <arm_group_label>Neurofeedback sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurofeedback sham</intervention_name>
    <arm_group_label>Neurofeedback sham</arm_group_label>
    <other_name>placebo neurofeedback, simulated neurofeedback</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Metacognitive Training</intervention_name>
    <arm_group_label>Metacognitive Training</arm_group_label>
    <other_name>cognitive behavioral therapy, group therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  ADHD diagnosis

          -  sufficient knowledge of the German language

        Exclusion criteria:

          -  psychiatric disorder(s) lifetime (bipolar disorder, schizophrenia,  schizoaffective
             disorder, borderline personality disorder)

          -  neurological disorder (e.g., epilepsy)

          -  current substance abuse disorder

          -  receives psychotherapy (e.g., CBT) or medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Schönenberg, Dr</last_name>
    <email>michael.schoenenberg@uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universität Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>February 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Michael Schoenenberg</investigator_full_name>
    <investigator_title>Efficacy of a Neurofeedback Treatment in Adults With ADHD: a Double-blind Randomized Placebo-controlled Study</investigator_title>
  </responsible_party>
  <keyword>ADHD, Neurofeedback, CBT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
